BioWorld

April 3, 2008

Medarex Shares Take Hit Amid Pfizer's Halted Melanoma Trial

Medarex shares plummeted Wednesday as partner Pfizer Inc. unexpectedly halted a Phase III trial of potential melanoma treatment tremelimumab. (BioWorld Today) Read More

Trial Data Could Prompt ISTA to Tweak Xibrom Formulations

Papers Agree on Lung Cancer Risk Genes, Disagree on Why

FDA Panel Supports Use of Noninferiority Studies for CAP

Genta Cutting Staff, Selling Ganite in Wake of Rejection

Generex Raising $20.7M Privately For Oral-lyn Insulin Spray Trials

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...

New 5-HT2C receptor agonists reported in Hansoh patent

BioWorld Science

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...